AADAC Polyclonal Antibody

• Background:

  Microsomal arylacetamide deacetylase competes against the activity of cytosolic arylamine N-acetyltransferase, which catalyzes one of the initial biotransformation pathways for arylamine and heterocyclic amine carcinogens. Arylacetamide deacetylation is an important enzyme activity in the metabolic activation of arylamine substrates to ultimate carcinogens. Displays major serine hydrolase activity in liver microsomes. Hydrolyzes also flutamide, which is an antiandrogen drug used for the treatment of prostate cancer that occasionally causes severe hepatotoxicity. Displays cellular triglyceride lipase activity in liver. Increases intracellular fatty acids derived from hydrolysis of newly formed triglyceride stores.

• Description:

  This is a AADAC Polyclonal Antibody from Reddot Biotech. This product is for Research Use Only.

• Synonyms:

  AAAD, Aada, Aadac, Arylacetamide deacetylase (esterase), Arylacetamide deacetylase, CES5A1, DAC

• Swiss Prot:

  P22760

• Accession Number:

  BC032309

• Reactivity:

  Human

• Immunogen:

  Recombinant protein of human AADAC

• Clonality:

  Polyclonal

• Conjugation:

  Unconjugated

• Type:

  Polyclonal Antibody

• Applications:

  WB, IHC, ELISA

• Purification Method:

  Affinity purification

• Assay Type:

  Antibody

• Concentration:

  0.2 mg/mL

• Dilution:

  WB 1:500-1:2000, IHC 1:25-1:100

• Buffer:

  PBS with 0.05% sodium azide and 50% glycerol, PH7.4

• Storage Conditions:

  Store at -20°C. Avoid freeze / thaw cycles.

• Calculated Molecular Weight:

  46 kDa

• Host or Source:

  Rabbit

• Isotype:

  IgG